U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545811) titled 'Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer' on April 16.
Brief Summary: This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).
Study Start Date: April 15
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Castration-resistant Prostate Cancer
Intervention:
BIOLOGICAL: JANX014
JANX014 will be administered via IV dosing
Recruitment St...